分组1 - Amedisys reported quarterly earnings of $0.96 per share, missing the Zacks Consensus Estimate of $1.05 per share, representing an earnings surprise of -8.57% [1] - The company posted revenues of $598.05 million for the quarter ended December 2024, slightly missing the Zacks Consensus Estimate by 0.02%, compared to year-ago revenues of $570.79 million [2] - Over the last four quarters, Amedisys has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] 分组2 - The current consensus EPS estimate for the coming quarter is $1.12 on revenues of $599.13 million, and for the current fiscal year, it is $4.84 on revenues of $2.47 billion [7] - The Zacks Industry Rank for Medical - Outpatient and Home Healthcare is currently in the top 24% of over 250 Zacks industries, indicating a favorable outlook for the industry [8] - Amedisys shares have added about 0.8% since the beginning of the year, underperforming the S&P 500's gain of 1.3% [3]

Financial Performance - Net service revenue increased by $27.3 million to $598.1 million in Q4 2024 compared to $570.8 million in Q4 2023[4] - For the full year 2024, net service revenue increased by $111.9 million to $2,348.3 million compared to $2,236.4 million in 2023[4] - Full year net income attributable to Amedisys, Inc. was $43.2 million, despite merger-related expenses totaling $66.6 million and a non-cash impairment charge of $48.4 million, compared to a net loss of $9.7 million in 2023[4] - Adjusted net income attributable to Amedisys, Inc. for the full year was $142.7 million, slightly up from $140.6 million in 2023[4] - The diluted earnings per share for Q4 2024 was a loss of $0.62, compared to earnings of $0.59 per share in Q4 2023[4] - The diluted EPS for the year ended December 31, 2024 was $3.01, compared to $4.60 for the year ended December 31, 2023[35] Operational Metrics - The company has approximately 19,000 employees and serves over 499,000 patients annually across 519 care centers[6] - Total assets increased to $2,138.7 million in 2024 from $2,060.2 million in 2023, representing a growth of 3.8%[15] - Total current assets rose to $632.1 million in 2024, a 27.2% increase from $496.9 million in 2023[15] - Total liabilities increased slightly to $958.7 million in 2024 from $940.4 million in 2023, a growth of 1.5%[15] - Cash, cash equivalents, and restricted cash at the end of the period reached $303.2 million, up from $138.9 million in 2023[16] - Days revenue outstanding improved to 43.0 days in 2024 from 47.7 days in 2023, reflecting better collection efficiency[17] Revenue Breakdown - Medicare revenue for the Home Health segment decreased by 4% to $212.4 million in Q4 2024, while Non-Medicare revenue increased by 19% to $164.6 million[20] - Medicare net service revenue for the year ended December 31, 2024, was $856.4 million, a decrease of 2% from $874.2 million in 2023[21] - Non-Medicare net service revenue increased by 19.7% to $634.1 million in 2024, compared to $529.4 million in 2023[21] - Hospice Medicare revenue for the year increased by 3.9% to $783.9 million, compared to $754.0 million in 2023[24] - Average Medicare revenue per completed episode increased to $3,030 in Q4 2024 from $2,997 in Q4 2023[20] - Total admissions rose by 11% to 441,945 in 2024, up from 399,752 in 2023[21] Expenses and Losses - Net loss attributable to Amedisys, Inc. was $20.4 million in Q4 2024, including merger-related expenses of $17.4 million and a non-cash goodwill impairment charge of $48.4 million, compared to a net income of $19.3 million in Q4 2023[4] - General and administrative expenses for the year increased to $264.8 million in 2024, up from $237.5 million in 2023[29] - High acuity care segment reported a total operating loss of $68.5 million for the year ended December 31, 2024, compared to a loss of $25.6 million in 2023[27] - Adjusted EBITDA for Q4 2024 was $54.6 million, down from $56.7 million in Q4 2023[4] - Adjusted EBITDA for the year ended December 31, 2024, was $245.8 million, slightly down from $247.0 million in 2023[31] - Merger-related expenses for the year ended December 31, 2024 totaled $66,638,000, an increase from $36,672,000 in the previous year[35] Mergers and Acquisitions - Amedisys will not conduct a quarterly earnings call due to the pending merger with UnitedHealth Group Incorporated[4] - The merger with UnitedHealth Group is expected to impact various operational aspects, including patient and provider relationships[9] - The company completed the sale of its personal care business on March 31, 2023, impacting revenue streams[28] Impairments and Adjustments - The company recorded an impairment expense of $48,391,000 for both the three-month and year ended December 31, 2024[35] - For the three-month period ended December 31, 2024, total certain items impacting net loss amounted to $57,802,000, with a net of tax impact of $52,337,000[35] - The total certain items impacting net loss for the year ended December 31, 2023 was $154,344,000, with a net of tax impact of $150,384,000[35] - The adjusted net income attributable to Amedisys, Inc. is calculated excluding certain items as defined in the financial notes[36] - Adjusted EBITDA is defined as net (loss) income before net interest expense, provision for income taxes, and depreciation and amortization, excluding certain items[36]

Core Viewpoint - Amedisys, Inc. reported its financial results for the fourth quarter and full year of 2024, highlighting significant changes in revenue, net income, and operational metrics amid a pending merger with UnitedHealth Group [1][2]. Financial Performance - Net service revenue for Q4 2024 increased by $27.3 million to $598.1 million compared to $570.8 million in Q4 2023 [4]. - For the full year 2024, net service revenue rose by $111.9 million to $2,348.3 million from $2,236.4 million in 2023 [4]. - The company reported a net loss attributable to Amedisys, Inc. of $20.4 million for Q4 2024, which included merger-related expenses of $17.4 million and a non-cash goodwill impairment charge of $48.4 million [4]. - In contrast, the net income attributable to Amedisys, Inc. for Q4 2023 was $19.3 million, which included merger-related expenses of $11.5 million [4]. - Adjusted EBITDA for Q4 2024 was $54.6 million, down from $56.7 million in Q4 2023 [4]. - For the full year 2024, adjusted net income attributable to Amedisys, Inc. was $142.7 million, compared to $140.6 million in 2023 [4]. Operational Metrics - The company experienced a decline in Medicare revenue by 4% in Q4 2024, while non-Medicare revenue increased by 19% [19]. - Total admissions for Q4 2024 rose by 8% to 109,686 compared to 101,809 in Q4 2023 [19]. - The average Medicare revenue per completed episode increased to $3,030 in Q4 2024 from $2,997 in Q4 2023 [19]. Balance Sheet Highlights - As of December 31, 2024, total assets were $2,138.7 million, up from $2,060.2 million in 2023 [14]. - Cash and cash equivalents increased significantly to $303.2 million from $126.5 million in 2023 [14]. - Total liabilities stood at $958.7 million, compared to $940.4 million in 2023 [14]. Segment Information - In the Home Health segment, net service revenue for Q4 2024 was $377.0 million, up from $358.9 million in Q4 2023 [19]. - The Hospice segment reported net service revenue of $212.9 million for Q4 2024, compared to $206.0 million in Q4 2023 [23]. - The High Acuity Care segment generated $8.1 million in net service revenue for Q4 2024, an increase from $5.9 million in Q4 2023 [26].

The market expects Amedisys (AMED) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, ...

BATON ROUGE, La., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care services, has recognized 47 employees with the prestigious Spirit of Excellence Awards, one of the company’s highest honors. “Every day, our employees bring warmth, compassion and clinical expertise into the homes of our patients, offering the care they need in the place they most want to be,” said Richard Ashworth, President and Chief Executive Officer. “We are ...

BATON ROUGE, La., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and high-acuity care services, has recognized 47 employees with the prestigious Spirit of Excellence Awards, one of the company's highest honors. "Every day, our employees bring warmth, compassion and clinical expertise into the homes of our patients, offering the care they need in the place they most want to be," said Richard Ashworth, President and Chief Executive Officer. "We are p ...

Key TakeawaysUnitedHealth Group and Amedisys agreed to extend the deadline to complete their $3.3 billion merger. The deal had been expected to be completed this week, but federal and state regulators moved to block it, and the challenge is currently before a Maryland court.The deal's new deadline is 10 days following the court's ruling or Dec. 31, 2025, whichever comes first. UnitedHealth Group (UNH) and Amedisys (AMED) agreed to extend the deadline to complete their $3.3 billion merger, after the U.S. Dep ...

Amedisys Inc AMED shares are trading higher on Friday after the company announced it extended its merger deadline with UnitedHealth Group Incorporated UNH.In an exchange filing, the companies entered into a waiver agreement, further advancing their merger deal, originally announced on June 26, 2023.Under the terms of the agreement, Merger Sub, a wholly owned subsidiary of UnitedHealth, will merge with Amedisys, with Amedisys continuing to operate as a subsidiary of UnitedHealth Group.The companies have agre ...

Core Insights - Amedisys, Inc. reported adjusted earnings per share (EPS) of $1.00 for Q3 2024, a 2% increase year over year, but missed the Zacks Consensus Estimate by 12.3% [1] - The company's net service revenues reached $587.7 million, reflecting a 5.7% year-over-year growth, but also fell short of the Zacks Consensus Estimate by 0.1% [3] - The impending merger with UnitedHealth Group's Optum is expected to close in the second half of 2024, aiming to enhance value-based care delivery [10] Financial Performance - The GAAP EPS was reported at 51 cents, down from 79 cents in the same period of 2023 [1] - Gross profit increased by 2.2% to $250.1 million, while gross margin decreased by 142 basis points to 42.6% due to an 8.3% rise in service costs [6] - Selling, General and Administrative (SG&A) expenses rose by 4.4% to $134.8 million, while adjusted operating profit was $58.5 million, a 0.4% increase year over year [7] Segment Analysis - Home Health division revenues totaled $372.1 million, up 5.8% year over year, with Medicare revenues decreasing by 2.7% to $212.1 million, while non-Medicare revenues increased by 19.7% to $160 million [4] - Hospice division revenues were $207.9 million, a 3.8% increase year over year, with Medicare revenues rising by 4.7% to $197.8 million, but non-Medicare revenues fell by 10.6% to $10.1 million [4] - The High Acuity Care segment reported revenues of $7.7 million, up from $4.4 million in the previous year [5] Liquidity and Cash Position - Amedisys ended Q3 2024 with cash and cash equivalents of $245.4 million, an increase from $149.9 million at the end of Q2 2024 [8] - Cumulative net cash provided by operating activities was $151.4 million, compared to $76.9 million a year ago [9] Merger Developments - The merger with UnitedHealth Group involves the sale of certain Amedisys home health care centers and UnitedHealth Group care centers to VCG Luna, LLC, contingent on the merger's successful closing [11]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share AMED The NASDAQ Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE ...